NDA 017808 · Mylan Ireland LTD
Miacalcin
Calcitonin Salmon · Injection · Calcitonin
Last checked: Nov 19, 2026Latest source record: Sep 11, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Jul 3, 1986
Approved uses
1
Original approval plus efficacy supplements
Registered trials
81
15 Phase 3, 11 recruiting
FAERS reports
3,123
2,212 serious, 279 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 15, 2024.
Miacalcin synthetic injection is a calcitonin, indicated for the following conditions: • Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable ( 1.1 ) • Treatment of hypercalcemia ( 1.2 ) • Treatment of postmenopausal osteoporosis when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.3 ) Limitations of Use: • Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.4 , 5.3 ) 1.1 Treatment of Paget’s Disease of Bone Miacalcin injection is indicated for the treatment of symptomatic Paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. There is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. Miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). 1.2 Treatment of Hypercalcemia Miacalcin injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. It may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. 1.3 Treatment of Postmenopausal Osteoporosis Miacalcin injection is indicated for the treatment of...
Mechanism: Calcitonin salmon is a calcitonin receptor agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastro-intestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 3, 1986 Original approval · Type 5 - New Formulation or New Manufacturer Other Important Information from FDA
2 products under this application
- MIACALCIN · CALCITONIN SALMON 100 IU/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- MIACALCIN · CALCITONIN SALMON 200 IU/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Calcitonin Salmon" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin DPivotal-lookingCompleted
Nordic Bioscience A/SIndustry
NCT00525798 · 4,665 participants · Start Mar 2007 · Primary completion Aug 2011
Drug: SMC021 Oral calcitonin; SMC021 Placebo · For: Osteoporosis
Sites: Gainesville, Georgia; Detroit, Michigan; Portland, Oregon · 16 sites in all
- Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing RegimensPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05217927 · 1,415 participants · Start Mar 4, 2022 · Primary completion Oct 22, 2024
Drug: Rimegepant 75mg daily dosing; Rimegepant 75mg every other day dosing and 1 more · For: Migraine
Sites: Tempe, Arizona; Colton, California; Los Angeles, California · 107 sites in all
- Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee OsteoarthritisPivotal-lookingCompleted
Nordic Bioscience A/SIndustry
NCT00486434 · 1,176 participants · Start May 2007 · Primary completion Sep 2010
Drug: SMC021 Oral Calcitonin; SMC021 Placebo · For: Osteoarthritis
Sites: Pardubice, Czechia; Aalborg, Denmark; Ballerup Municipality, Denmark · 9 sites in all
- Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic MigrainePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT02621931 · 1,130 participants · Start Mar 22, 2016 · Primary completion Apr 11, 2017
Drug: Fremanezumab; Placebo · For: Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 273 sites in all
- Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)Pivotal-lookingTerminated
Nordic Bioscience A/SIndustry
NCT00704847 · 1,030 participants · Start Jun 2008 · Primary completion May 2011
Drug: Oral Salmon Calcitonin; Oral Salmon Calcitonin (Placebo) · For: Osteoarthritis
Sites: Tuscaloosa, Alabama; Sacramento, California; Chicago, Illinois · 18 sites in all
- Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03333109 · 900 participants · Start Feb 8, 2018 · Primary completion Jan 13, 2020
Drug: Erenumab · For: Episodic Migraine
Sites: CABA, Argentina; Buenos Aires, Argentina; Ciudad Autonoma de Bs As, Argentina · 81 sites in all
- Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic MigrainePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT02629861 · 875 participants · Start Mar 23, 2016 · Primary completion Apr 10, 2017
Drug: Fremanezumab; Placebo · For: Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 275 sites in all
- Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic MigrainePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03828539 · 777 participants · Start Feb 22, 2019 · Primary completion Jul 29, 2020
Drug: Erenumab; Topiramate and 2 more · For: Migraine
Sites: Stuttgart, Germany; Marburg Wehrda, Germany; Hanover, Germany · 79 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea253
- drug ineffective249
- fall221
- pain213
- arthralgia189
- dizziness184
- headache178
- back pain173
- dyspnoea164
- asthenia156
- fatigue156
- diarrhoea146
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 429 |
| 2005 | 335 |
| 2006 | 243 |
| 2007 | 144 |
| 2008 | 152 |
| 2009 | 150 |
| 2010 | 176 |
| 2011 | 176 |
| 2012 | 212 |
| 2013 | 63 |
| 2014 | 65 |
| 2015 | 142 |
| 2016 | 112 |
| 2017 | 108 |
| 2018 | 81 |
| 2019 | 91 |
| 2020 | 55 |
| 2021 | 39 |
| 2022 | 73 |
| 2023 | 81 |
| 2024 | 73 |
| 2025 | 79 |
| 2026 | 44 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Miacalcin (Calcitonin,Salmon,Synthetic)
2024 spending
$712K
Beneficiaries
13
45 claims
Per beneficiary
$54,768
$1,338.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,154,663 |
| 2021 | $3,173,521 |
| 2022 | $980,104 |
| 2023 | $836,655 |
| 2024 | $711,979 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
Kesselheim AS, Polinski JM, Fulchino LA, et al. · Drugs 2015 · Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- Can calcitonin nasal spray reduce the risk of recurrence of central giant cell granuloma of the jaws? A double-blind clinical trial.
Tabrizi R, Fardisi S, Zamiri B, et al. · Int J Oral Maxillofac Surg 2016 · Randomized Controlled Trial
- Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K, Lindsay R, Christiansen C · Clin Ther 1995 · Clinical Trial, Randomized Controlled Trial
- Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation.
Coyle D, Cranney A, Lee KM, et al. · Pharmacoeconomics 2001 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Mylan Ireland LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.